GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

Second-quarter sales rose to £7.99 billion from £7.88 billion in the same period the year prior.

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

Shares of GSK PLC GSK slid 3.04% to £14.18 Thursday, on what proved to be an all-around rough trading session for the stock ...

Over 100 employees from GSK’s Hamilton site recently rolled up their sleeves for their annual "Together Days," a volunteer ...